News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends

Jun 1, 2000
Bruce J. Dezube, MD
Publication
Article
OncologyONCOLOGY Vol 14 No 6
Volume 14
Issue 6

In his excellent review, Dr. Mitsuyasu correctly highlights the three most important ingredients that play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS)-Kaposi’s sarcoma herpesvirus/human herpesvirus type 8 (KSHV/HHV-8); altered expression and response to cytokines; and stimulation of KS growth by the human immunodeficiency virus (HIV)-1 trans-activating protein, Tat. Recent studies have provided tremendous insight into the process whereby KSHV/HHV-8 creates the inflammatory-angiogenic state that characterizes KS.

In his excellent review, Dr. Mitsuyasu correctly highlights the three most important ingredients that play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS)—Kaposi’s sarcoma herpesvirus/human herpesvirus type 8 (KSHV/HHV-8); altered expression and response to cytokines; and stimulation of KS growth by the human immunodeficiency virus (HIV)-1 trans-activating protein, Tat. Recent studies have provided tremendous insight into the process whereby KSHV/HHV-8 creates the inflammatory-angiogenic state that characterizes KS.

The clinical course of AIDS-related KS is highly variable, ranging from minimal stable disease to explosive growth. The psychosocial burden associated with KS may be profound, a point illustrated both by this review and by the movie, Philadelphia, in which Tom Hanks portrays a gay man with KS. The treatment algorithm put forth by Dr. Mitsuyasu is appropriate; differences between his and my approaches are outlined below.

Creation of an Inflammatory-Angiogenic Environment

KSHV/HHV-8 is a necessary, but not sufficient, cause of KS. The virus encodes proteins that are homologs of interleukin-6 (IL-6), chemokines of the macrophage inflammatory protein family, cell-cycle regulators of the cyclin family, and antiapoptosis genes of the bcl-2 family. The HIV-1 protein, Tat, promotes the growth of spindle cells of endothelial origin, but does so only in the presence of inflammatory cytokines.[1]

The synergy between cytokines and the HIV-1 Tat protein, as well as the immunosuppression associated with AIDS, provide possible insight into the reasons why AIDS-related KS is more aggressive than the classic Mediterranean form, in which the HIV-1 Tat protein does not play a role. The remarkable finding that KSHV/HHV-8 encodes viral IL-6, and the equally remarkable finding that this IL-6, in turn, leads to expression of the angiogenic vascular endothelial growth factor (VEGF),[2] provide a missing link in the chain of events by which KSHV/HHV-8 creates an inflammatory-angiogenic environment.[3]

Treatment

The major goals of treatment for KS, as outlined by Dr. Mitsuyasu, are palliation of symptoms; shrinkage of tumor to alleviate edema, organ compromise, or psychological stress; and prevention of disease progression. Treatment options depend greatly on the tumor (extent of disease and rate of growth), the HIV-1 viral load, and the host (CD4+ T-lymphocyte count, overall medical condition).

Highly Active Antiretroviral Therapy

Most, if not all, KS patients should be advised to take antiretroviral drugs that will maximally decrease the HIV-1 viral load. This recommendation is based on the increasing recognition that effective antiretroviral regimens are associated with both a decrease in the proportion of new AIDS-defining KS cases and a regression in the size of existing KS lesions.[4] Highly active antiretroviral therapy (HAART) prolongs the time to treatment failure of anti-KS therapies.[5]

Local Therapy

Alitretinoin gel 0.1% (Panretin) is a topical, patient-administered therapy for the treatment of KS. Alitretinoin gel, as compared to vehicle gel, is associated with a shorter time to tumor response, more prolonged duration of response, and more prolonged time to disease progression.[6] Responses, which typically occur after 4 to 8 weeks, are seen in patients with a wide range of baseline CD4+ T-lymphocyte counts. Dermal irritation may occur at the site of application.

Other effective local treatments include intralesional chemotherapy, radiation therapy, laser therapy, and cryotherapy. Vinblastine is probably the most widely used intralesional agent, with an excellent response rate of approximately 70%. Radiation therapy can very effectively palliate symptomatic disease that is too extensive to be treated with intralesional chemotherapy, but not extensive enough to warrant systemic therapy. Local therapies, in general, will not affect the development of new lesions in untreated areas.

Interferon-alfa

Interferon-alfa is a biological response modifier that can produce clinically significant responses in KS patients, especially in those with disease limited to the skin and with relatively modest degrees of immunosuppression.[7] Poor tumor response and drug-related toxicity are particularly striking in patients with CD4+ T-lymphocyte counts < 200 cells/µL. For some patients with asymptomatic, but relatively disseminated, cutaneous disease, interferon in combination with antiretroviral agents may be a reasonable option prior to the decision to use chemotherapy.

Chemotherapy

Current systemic treatments for KS revolve around the newer liposomal anthracyclines, as well as paclitaxel (Taxol). Although Dr. Mitsuyasu provides a section on combination chemotherapy, such as ABV (Adriamycin, bleomycin, vincristine) and BV (bleomycin, vincristine), I would consider these regimens to be passé.

The two currently approved liposomal anthracyclines, liposomal doxorubicin (Doxil) and liposomal daunorubicin (DaunoXome), have become the first-line chemotherapeutic treatments for patients with disseminated, symptomatic KS. Compared to conventional chemotherapy, the liposomal formulations of the anthracyclines provide the theoretical advantage of a longer plasma half-life, higher tumor concentrations of drug, and less toxicity in nontarget organs.

In randomized, multicenter trials, each of these liposomal agents has been found to be superior to conventional chemotherapy (bleomycin [Blenoxane] and vincristine with or without nonliposomal doxorubicin) in terms of response rates and toxicity profiles.[8,9] Side effects are, in general, quite mild; alopecia, neuropathy, and cardiomyopathy, in particular, are unusual with these liposomal preparations.

Paclitaxel is the newest systemic chemotherapeutic agent approved for KS, with striking efficacy (response rates as high as 75%)—even for patients with anthracycline-resistant disease.[10,11] The median duration of response of approximately 10 months is among the longest observed for any regimen reported for this disease.[10] Paclitaxel is well tolerated, but the higher prevalences of alopecia, myalgia/arthralgia, bone-marrow suppression, and the need for a 3-hour infusion make paclitaxel less attractive than the liposomal anthracyclines as initial therapy for disseminated disease.

An ongoing study, conducted by the Eastern Cooperative Oncology Group and the AIDS Malignancy Consortium (ECOG/AMC), is currently comparing paclitaxel to liposomal doxorubicin in patients with previously untreated advanced KS.

Antiretroviral Therapy/Paclitaxel: Potential Interactions

The drug metabolism of many of the approved antiretroviral agents, particularly protease inhibitors and nonnucleoside reverse transcriptase inhibitors, involves cytochrome P450 metabolic pathways. Taxanes are oxidized to less active metabolites by hepatic cytochrome P450 enzymes. An ECOG/AMC study is currently assessing the pharmacokinetic interactions between paclitaxel and protease inhibitors. Caution is urged when coadministering agents that utilize the same metabolic pathways.

Future Directions

Given the highly significant role that angiogenesis plays in the pathogenesis of KS, it is not surprising that many, if not most, of the angiogenesis inhibitors in development have been, or are currently being, tested in patients with AIDS-related KS. IM862, an intranasally administered VEGF inhibitor, is being tested in a phase III trial under the auspices of the NCI. In a phase II trial of IM862 in 44 patients, the overall response rate was 36% and adverse events were mild and transient.[12]

Other angiogenesis inhibitors, which have led to durable clinical responses in patients accrued to early trials, include fumagillin,[13] thalidomide (Thalomid),[14] metastat (col-3, a matrix metalloproteinase inhibitor),[15] interleukin-12,[16] and SU-5416 (a VEGF inhibitor). Other potential targets for KS therapies include KSHV/HHV-8, sex hormones, and the process of cellular differentiation.

Each of these targets serves as the rationale for current ongoing pathogenesis-based clinical trials. Virtually all patients with KS can derive benefit from the many approved and investigational agents developed through years of collaborative translational and clinical research.

References:

1. Ensoli B, Gendelman R, Markham P, et al: Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi’s sarcoma. Nature 371:674-680, 1994.

2. Aoki Y, Jaffe ES, Chang Y, et al: Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034-4043, 1999.

3. Mesri EA: Inflammatory reactivation and angiogenicity of Kaposi’s sarcoma-associated herpesvirus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi’s sarcoma. Blood 93:4031-4033, 1999.

4. Dezube BJ: AIDS-related Kaposi’s sarcoma: Clinical features, staging, and treatment. Semin Oncol vol 27, 2000 (in press).

5. Bower M, Fox P, Fife K, et al: HAART prolongs time-to-treatment failure in Kaposi’s sarcoma: Programs and Abstracts of the 3rd National AIDS Malignancy Conference, Bethesda, MD (abstract). J Acquir Immune Defic Syndr Hum Retrovirol 21(58):a24, 1999.

6. Walmsley S, Northfelt DW, Melosky B, et al: Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic) gel. J Acquir Immune Defic Syndr Hum Retrovirol 22:235-246, 1999.

7. Shepherd FA, Beaulieu R, Gelmon K, et al: Prospective, randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study. J Clin Oncol 16:1736-1742, 1998.

8. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 14:2353-2364, 1996.

9. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451, 1998.

10. Gill PS, Tulpule A, Espina BM, et al: Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 17:1876-1883, 1999.

11. Welles L, Saville MW, Lietzau J, et al: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 16:1112-1121, 1998.

12. Tupule A, Scadden DT, Espina BM, et al: Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 18:716-723, 2000.

13. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al: Fumagillin analog in the treatment of Kaposi’s sarcoma: A phase I AIDS Clinical Trial Group study. J Clin Oncol 16:1444-1449, 1998.

14. Little R, Welles L, Wyvill K, et al: Preliminary results of a phase II study of oral thalidomide in patients with AIDS-related Kaposi’s sarcoma: Programs and Abstracts of the 2nd AIDS Malignancy Conference, Bethesda, Md (abstract). J Acquir Immune Defic Syndr Hum Retrovirol 17(18):a16, 1998.

15. Cianfrocca M, Cooley TP, Lee J, et al: Angiogenesis inhibitor col-3 in the treatment of HIV-related Kaposi’s sarcoma—A phase I AIDS Malignancy Consortium study: Programs and Abstracts of the 4th National AIDS Malignancy Conference, Bethesda, Md. J Acquir Immune Defic Syndr Hum Retrovirol 2000 (in press).

16. Pluda JM, Wyvill K, Little R: Administration of interleukin-12 to patients with AIDS-associated Kaposi’s sarcoma—Preliminary results of a pilot study: Programs and Abstracts of the 3rd National AIDS Malignancy Conference, Bethesda, Md (abstract). J Acquir Immune Defic Syndr Hum Retrovirol 21(78):a29, 1999.

Articles in this issue

Purine Nucleoside Analogs in Indolent Non-Hodgkin’s Lymphoma
Magnetic Resonance Imaging of the Abdomen: Applications in the Oncology Patient
New Website Addresses Epidermal Growth Factor Receptors in Cancer Therapy
Common p53 Gene Test Helps Predict Cancer Recurrence in Mastectomy Patients
Promising Results With Targeted Drug Delivery System for Primary Liver Cancer
New Treatment Guidelines Available for Colon and Rectal Cancer Patients
Breath Test Identifies Patients Who Should Get Lower Chemotherapy Doses
ADA Inhibitors: Recent Developments and Future Directions in Low-Grade Lymphoma
Encouraging Results Achieved Using Topotecan as Salvage Therapy in Recurrent Ovarian Cancer
3D CRT More Cost-Effective Than Conventional RT for Prostate Cancer
Economic Consequences of Cancer Treatment–Related Fatigue
Capecitabine Demonstrates Favorable Response Rates in Advanced Colorectal Cancer Patients
Senate Bill Would Limit Prices Drug Companies Could Charge
Support for &#145;Minority Report&#146; on Mammography for Women in Their 40s
Research Challenges Conventional Thinking About Prostate Cancer Treatment
Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

August 1st 2023

Olaparib Combo Provides Meaningful Benefit in Uterine Leiomyosarcoma

August 21st 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

TKI and Immunotherapy Trials Bring ‘Excitement’ to Sarcoma Space

July 28th 2023

Tailoring Treatment Strategies Is Paramount in the Sarcoma Space

July 25th 2023

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

August 1st 2023

Olaparib Combo Provides Meaningful Benefit in Uterine Leiomyosarcoma

August 21st 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

TKI and Immunotherapy Trials Bring ‘Excitement’ to Sarcoma Space

July 28th 2023

Tailoring Treatment Strategies Is Paramount in the Sarcoma Space

July 25th 2023

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

August 1st 2023

Olaparib Combo Provides Meaningful Benefit in Uterine Leiomyosarcoma

August 21st 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

TKI and Immunotherapy Trials Bring ‘Excitement’ to Sarcoma Space

July 28th 2023

Tailoring Treatment Strategies Is Paramount in the Sarcoma Space

July 25th 2023
Related Content
Advertisement

A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023
Article

A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


Olaparib plus temozolomide appears to prolong median progression-free survival for those with homologous recombination deficient uterine leiomyosarcoma compared with homologous recombination proficient tumors.

Olaparib Combo Provides Meaningful Benefit in Uterine Leiomyosarcoma

August 21st 2023
Article

Olaparib plus temozolomide appears to prolong median progression-free survival for those with homologous recombination deficient uterine leiomyosarcoma compared with homologous recombination proficient tumors.


Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017
Podcast

In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.


Brian Van Tine, MD, PhD, discusses clinical trials assessing several regimens that may lead to novel treatment options for those with desmoid tumors, dedifferentiated liposarcoma, and other hard-to-treat sarcoma subtypes.

TKI and Immunotherapy Trials Bring ‘Excitement’ to Sarcoma Space

July 28th 2023
Article

Brian Van Tine, MD, PhD, discusses clinical trials assessing several regimens that may lead to novel treatment options for those with desmoid tumors, dedifferentiated liposarcoma, and other hard-to-treat sarcoma subtypes.


Sandra P. D’Angelo, MD, reviews current treatments in sarcoma, and how she interacts with her multidisciplinary counterparts to offer the best care to her patients.

Tailoring Treatment Strategies Is Paramount in the Sarcoma Space

July 25th 2023
Article

Sandra P. D’Angelo, MD, reviews current treatments in sarcoma, and how she interacts with her multidisciplinary counterparts to offer the best care to her patients.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.